<DOC>
	<DOCNO>NCT00363350</DOCNO>
	<brief_summary>This study evaluation effect rituximab compare placebo combination steroid salivary flow serological clinical parameter patient primary SS .</brief_summary>
	<brief_title>Rituximab Treatment Sjogren 's Syndrome</brief_title>
	<detailed_description>Study design : phase II trial Study objective : evaluation effect rituximab compare placebo combination steroid salivary flow serological clinical parameter patient primary SS Number participate centre : 1 Duration : follow-up 48 week Study medication : 2 infusion day 1 day 15 rituximab infusion ( 1000 mg ) placebo infusion intravenous infusion 100 mg methylprednisolone infusion rituximab ( placebo rituximab ) , together 60 mg per day oral prednisone day 2 , 3 , 16 17 , 30 mg per day day 4 , 5 , 18 19 15 mg per day day 6 20 Primary objective/endpoint : stimulate salivary gland function ( stimulate submandibular/sublingual parotid saliva ) Secondary objectives/endpoint : Functional parameter Laboratory parameter Subjective parameter Histological/Molecular parameter Number subject : 30 patient primary SS ( 20 patient rituximab treatment , 10 patient placebo )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Stimulated whole saliva secretion â‰¥ 0,15 ml/min Male female &gt; 18 year Primary SS accord revise European U.S. criterion ( 22 ) Positive autoantibody ( IgMRf &gt; 10 SSA and/or SSB ) Parotid gland biopsy ( paraffine material fresh frozen tissue ) characteristic feature SS perform time inclusion ( long 12 month ago ) Use reliable method contraception study Written inform consent The presence connective tissue disease Preceding treatment antiTNF monoclonal antibody Use prednisone , hydroxychloroquine le 1 month ago Use MTX , cyclophosphamide , cyclosporin , azathioprine DMARDS le 0,5 year ago Serum creatine &gt; 2.8 mg/dl ( 250 micromol/l ) ASAT ALAT outside 1.5 x upper normal range laboratory Hb &lt; 9 g/dl ( 5.6 mmol/l ) males 8.5 g/dl ( 5.3 mmol/l ) females Neutrophil granulocytes less 0.5 x 109/l Platelet count le 50 x 109/l Positive pregnancy test breastfeed History alcohol drug abuse Serious infection Underlying cardiac , pulmonary , metabolic , renal gastrointestinal condition , chronic latent infectious disease immune deficiency place patient unacceptable risk participation study History malignancy exception completely resect basal cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>